TPP+ (triphenylphosphonium)
The lipophilic cation that concentrates drugs inside the mitochondrion up to ~1,000-fold
Definition
TPP+ (the triphenylphosphonium cation) is a lipophilic, positively charged molecule used as a "delivery vehicle" to target drugs and antioxidants specifically to the inside of the mitochondrion. Its positive charge is drawn by the mitochondrial membrane potential (negative on the inside), so any compound covalently bound to TPP+ accumulates several hundred-fold — up to ~1,000x — within the mitochondrial matrix. This is the technology that lets antioxidants such as MitoQ (CoQ10 conjugated to TPP+) actually reach the mitochondrion, which standard CoQ10 barely achieves.
Detailed explanation
TPP+ was developed as a mitochondrial-targeting strategy by Michael Murphy and Robin Smith at the University of Otago (New Zealand), with the foundational MitoQ synthesis published in the Journal of Biological Chemistry in 2001 (Kelso et al.).
The mechanism rests on electrochemical physics: the inner mitochondrial membrane maintains a membrane potential of −150 to −180 mV (interior negative), generated by the electron transport chain. Because TPP+ is a delocalized, lipophilic cation, it crosses lipid membranes without transporters and is driven toward the most electronegative compartment. By the Nernst equation, every −60 mV of potential concentrates the cation ~10-fold; across the combined plasma and mitochondrial gradients, intramitochondrial accumulation reaches several hundred to a thousand times the external concentration.
This platform has yielded a whole family of "mito-targeted" molecules (MitoQ, MitoVitE, MitoTEMPO, TMRM-type fluorescent probes). Its constraint is safety: at high doses TPP+ itself can depolarize the mitochondrion and inhibit Krebs-cycle enzymes, so dosing is calibrated to deliver antioxidant action without toxicity.
Scientific sources
- PubMed — Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties (Kelso, Smith, Murphy — J Biol Chem 2001)
- PubMed — Targeting antioxidants to mitochondria by conjugation to lipophilic cations (Murphy & Smith — Annu Rev Pharmacol Toxicol 2007)
- PubMed — Understanding and preventing mitochondrial oxidative damage (Murphy — Biochem Soc Trans 2016)
- PubMed — Animal and human studies with the mitochondria-targeted antioxidant MitoQ (Smith & Murphy — Ann N Y Acad Sci 2010)
Interested in related treatments?
Generate My Protocol